Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : SYNSORB (T.SYB)(SYBBF) CURE FOR CANCER? -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (124)	8/28/2000 6:58:04 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 164

semi-OT:Aug. 28, 2000--Oncolytics Biotech Inc. ("Oncolytics") (TSE:ONC.) today reported its results for the second quarter and six month period ended June 30, 2000. For the second quarter, the total loss was $1,273,755 or $0.08 per share. For the first half of 2000 the total loss was $1,543,667 or $0.10 per share. As expected, the Company reported no revenue for the period as its products are still under development. "The second quarter of 2000 has been a very dynamic period for Oncolytics," said Mr. Douglas Ball, Chief Financial Officer of Oncolytics. "In addition to commencing a Phase I trial on Reolysin(R), Oncolytics also listed on the Toronto Stock Exchange (TSE:ONC), successfully completed initial animal toxicology testing, and announced positive results from a bladder cancer study in animals. In all, it was a very positive quarter for Oncolytics." A milestone payment of $1,000,000 was accrued as payable to the original shareholders of Oncolytics as a result of a successful completion of animal toxicology, a pre-condition to the commencement of Phase I clinical trials of Reolysin(R). This accrual increased development expenses in the second quarter to $1,295,252, bringing total development expenses for the first half of 2000 to $1,629,345. Expenses associated with the commencement and continuation of the Reolysin(R) clinical program, as well as the costs of expanding the Corporation's market exposure through a listing on the Toronto Stock Exchange, resulted in operating expenses for the second quarter 2000 of $243,459 for total year to date operating expenses of $317,139. The Company's total expenses for the first half of 2000 were $1,949,103 or $1,540,104 for the second quarter, primarily as a result of the milestone payment and clinical trial activities. As at June 30, 2000 the Company's cash and cash equivalents balance was $17,164,590 as compared to $4,549,177 as at December 31, 1999. Oncolytics concluded a successful warrant offering in the first quarter 2000 that raised net proceeds of $13,109,657. SNIP<> Jim